These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29911695)

  • 41. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
    Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
    Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Updates in chronic graft-versus-host disease management.
    Malard F; Mohty M
    Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era.
    Vadakkel G; Eng S; Proli A; Ponce DM
    Bone Marrow Transplant; 2024 Oct; 59(10):1360-1368. PubMed ID: 39080470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
    Kim DDH; Popradi G; Lepic K; Paulson K; Allan D; Nampoothiri RV; Lachance S; Deotare U; White J; Elemary M; Jamani K; Fraga C; Lemieux C; Novitzky-Basso I; Law AD; Kumar R; Walker I; Schultz KR;
    Curr Oncol; 2024 Mar; 31(3):1426-1444. PubMed ID: 38534941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective study of female genital chronic graft-versus-host disease symptoms, signs, diagnosis and treatment.
    Smith Knutsson E; Björk Y; Broman AK; Helström L; Nicklasson M; Brune M; Sundfeldt K
    Acta Obstet Gynecol Scand; 2018 Sep; 97(9):1122-1129. PubMed ID: 29752810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
    Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
    Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Dreger P; Michallet M; Bosman P; Dietrich S; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Niederwieser D; Müller L; Vandenberghe E; Scortechini I; Schoemans H; Andersen NS; Finke J; Russo D; Ljungman P; Passweg J; van Gelder M; Durakovic N; Labussiere-Wallet H; Berg T; Wulf G; Bethge W; Bunjes D; Stilgenbauer S; Canepari ME; Schaap M; Fox CP; Kröger N; Montoto S; Schetelig J
    Bone Marrow Transplant; 2019 Jan; 54(1):44-52. PubMed ID: 29728701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
    Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I
    Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extensive dental caries in patients with oral chronic graft-versus-host disease.
    Castellarin P; Stevenson K; Biasotto M; Yuan A; Woo SB; Treister NS
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1573-9. PubMed ID: 22516054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
    Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
    Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
    Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
    Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
    Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
    Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease.
    Asano T; Matsuoka KI; Iyama S; Ohashi K; Inamoto Y; Ohwada C; Murata M; Satake A; Yoshida C; Nakase K; Mori Y; Tanimoto M
    Acta Med Okayama; 2016 Oct; 70(5):429-433. PubMed ID: 27777442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
    Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
    Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.